Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.
Understanding Hyperkalemia Risk, Effect on Benefits with Finerenone, with Orly Vardeny, PharmD, MS
Orly Vardeny, PharmD, MS, discusses the management and monitoring of hyperkalemia among patients with heart failure with preserved ejection fraction using finerenone.
Biomarkers for IgAN
Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.
IgAN vs Other Glomerular Diseases
Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Just discussed data from 2 studies demonstrating efficacy of AI assessment compared to clinician assessment.
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban
Christian. T. Ruff, MD, MPH describes an analysis of AZALEA-TIMI 71 demonstrating the substantial benefit of abelacimab on bleeding outcomes in patients on antiplatelet therapy.
Understanding NUDGLE-FLU Data from AHA 2024, with Ankeet Bhatt, MD, MBA, ScM
Ankeet Bhatt, MD, MBA, ScM, provides additional insight into NUDGE-FLU data he presented at AHA 2024.
Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage in HFpEF
Barry A. Borlaug, MD describes the beneficial effect of tirzepatide on circulatory pressure-volume overload and end-organ damage in patients with HFpEF and obesity.
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.
Oussama Wazni, MD, MBA: OPTION Trial and the Role of LAAC in Atrial Fibrillation
Oussama Wazni, MD, discusses the results of the OPTION trial examining LAAC in atrial fibrillation as well as its reception as AHA 2024.
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.
Rapid Initiation of SGLT2 Inhibitors Improves Cost-Effectiveness of Therapy, with Ankeet Bhatt, MD, MBA
Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data
In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.
The APAC Recap: Lifestyle Medicine at CAPP Live 2024 with Laura Ross, PA-C
Laura Ross, PA-C, shares insights from the inaugural CAPP meeting on how lifestyle medicine and targeted therapies are transforming cardiovascular care.
Diabetes Dialogue: Latest Updates on Semaglutide
In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.
The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C
Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
In this latest episode of Lungcast, multiple points of view are highlighted regarding Aspirin-Exacerbated Respiratory Disease (AERD).
Ahmad Masri, MD, MS: Reaching New Milestones in Cardiovascular Gene Therapy Development
Masri discussed the new phase 3 trial of Intellia’s NTLA-2001 or nex-z.
Naim Alkhouri, MD: First Real-World Data for Resmetirom Use in Clinical Practice
Alkhouri explains the first real-world data on the use of resmetirom (Rezdiffra) in patients with MASH and how they compare to clinical trial findings.
Ellen Sher, MD: Cross-Specialty Collaboration Can Improve Atopic Dermatitis Management
IgAN Progression
Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).
Overview of IgAN and Its Common Symptoms
Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.
Novel Gas-Sensing Capsule May Provide New Tool for Assessing Motility Disorders
Braden Kuo, MD, explains how the gas-sensing capsule compares to the FDA-cleared, but now discontinued, SmartPill wireless motility capsule.
Stool Diary App Aids Vibrating Capsule Compliance, Efficacy for Chronic Constipation
Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.
Mazen Noureddin, MD: Differences in Resmetirom Efficacy Based on Body Weight, BMI
Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.
